Biomedica is the parent company of a group that operates in 13 countries across Europe and has approximately 280 employees. Biomedica supplies, like AddLife, products and services in laboratory engineering and medical technology to mainly publicly funded healthcare. Through the acquisition of Biomedica, AddLife established a strong base in Europe and extends its geographic market from a population of about 32 million people to about 164 million people.
The acquisition agreement was signed on 26 November 2018. The total purchase price for the acquisition of Biomedica was approx. EUR 39 million, of which 75 % is paid in cash through existing credit facilities and 25 % through newly issued Class B shares in AddLife.
Schellenberg Wittmer advised AddLife alongside Swedish law firm Delphi on the transaction, in particular in regards to the due diligence in Switzerland. The team consisted of partner Oliver Triebold (corporate/M&A; overall lead) and associates Zlatina Iliev and Mirjam Schneider (both corporate/M&A) and Samuel Jost (competition).